

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Neil David Palmisiano, MD, MS

eRA COMMONS USERNAME (credential, e.g., agency login): nxp009

POSITION TITLE: Associate Professor

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
The Pennsylvania State University	BS	05/2004	Biology
Temple University School of Medicine	MD	06/2008	Medicine
Thomas Jefferson University	Residency	06/2011	Internal Medicine
Thomas Jefferson University	MS	06/2014	Pharmacology
Thomas Jefferson University	Fellowship	06/2014	Hematology/Oncology

A. Personal Statement

My academic career has consistently focused on hematologic malignancies, primarily AML, ALL, and MDS, including the role of hematopoietic stem cell transplantation in these diseases. My clinical research effort over the past 10 years has increasingly been focused on designing and conducting IIT Phase I and Phase II trials in acute leukemia and MDS, many of which are based on pre-clinical work conducted with intramural and extramural translational scientists. My training in Pharmacology has been instrumental in facilitating and supporting my clinical research work. Over the past three years I have designed the concepts and written the protocols for six early phase clinical trials in MDS, AML and ALL with the incorporation of novel biomarkers to predict response, and I am working within cooperative groups to increase enrollment in trials for various subtypes of these malignancies. I am currently the national PI on a phase I/II trial in ALL run through the Eastern Cooperative Oncology Group (ECOG-ACRIN). My work in ECOG-ACRIN has given me a broad view and experience in overseeing a large, multi-site clinical trial and has taught me many new leadership and organizational skills. At Rutgers Cancer Institute of New Jersey I serve in several administrative roles. As system leader for leukemia, I am responsible for the development of system-wide treatment standards and the curation of a research portfolio that serves both the needs of our main academic site as well as our community partners. I serve as the deputy director of CINJ's phase I program where I am responsible for the development of an early phase clinical research program in hematologic malignancies. In this role as well - as previous role as co-director for operations of Jefferson University's Phase I Program - I have been the site PI on 13 early phase clinical trials. Lastly, I am a co-Medical Director of the Office of Human Subjects Research where I am responsible for providing medical direction for the operations of OHRS and ensuring quality assurance/quality control of services provided by the OHRS, as well as for oversight of the day-to-day operations. I also serve as a medical resource and liaison between CINJ clinical researchers and OHRS. My role on the Cancer Center Support Grant is co-Chair of the Scientific Review Board (Protocol Review and Monitoring System).

Ongoing and recently completed projects that I would like to highlight include:

AbbVie

9/2020 to present

A Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Role: Overall PI (IIT)

NCI 3P30CA056036-21S5

PI: Karen Knudsen; Role: Co-investigator

9/2020 to present

A SKCC Tobacco Cessation Treatment Program at Jefferson: A Hybrid Model of Point of Care Treatment Delivery with a Tobacco Treatment Specialist Follow-Up Approach

Cyteir Therapeutics

11/2019 to present

A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor

AbbVie

4/2016 to present

A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Role – ECOG Overall Study Chair (IIT)

Genentech

9/2018 to present

A phase I study of Venetoclax + Lenalidomide + Rituximab Hyaluronidase in Relapsed or Refractory (R/R) indolent Non-Hodgkin's Lymphoma (iNHL)

Role – Overall PI (IIT)

Thomas Jefferson University Institutional Grant

10/2015 to present

A phase I Biomarker Study to Evaluate Clinical Response to Sirolimus and MEC Treatment in Patients with AML

Role: Overall PI (IIT)

Thomas Jefferson University Institutional Grant

7/2013 to 8/2019

A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome

Role: Overall PI (IIT)

B. Positions and Honors

Positions and Employment

2014-2016	Assistant Professor of Medicine, Penn State Hershey Medical Center, Hershey, PA
2014-2016	Physician Quality Leader, Medical Oncology, Penn State Hershey Medical Center, Hershey, PA
2016-2021	Assistant Professor of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA
2018-2021	Associate Program Director, Hematology/Medical Oncology Fellowship, Thomas Jefferson University Hospital, Philadelphia, PA
2020-present	Co-Director for Clinical Operations, Phase I/Early Drug Development Program, Thomas Jefferson University Hospital, Philadelphia, PA
2021-present	Associate Professor of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA

Scientific Committees, Editorial Boards

2014-present	ECOG-ACRIN Leukemia Committee
2019-present	American Society of Hematology, Abstract Reviewer in Acute Lymphoblastic Leukemia
2018-2019	American Society of Hematology, Advocacy Leadership Institute Member
2019-Present	American Society of Hematology, Member, ASH Foundation Committee

Clinical Trial Leadership

2018-present Overall Study Chair, ECOG-ACRIN 9152: Phase Ib/II in ALL

2019-present Younger Adult AML Working Group, ECOG-ACRIN

2018-present Data Safety and Monitoring Committee, Bayer 19420, FIH Phase 1A in AML

2019-present Data Safety and Monitoring Committee, Oncotartis OT-82-001, FIH Phase IA in Lymphoma

C. Contributions to Science

1. **Improving therapy of ALL/AML/MDS via clinical trials and novel biomarkers:** I have focused on the development of early phase clinical trials and drug development in acute leukemia and lymphoma. I have recently focused on authoring trials for relapsed and refractory acute leukemias and lymphomas using bcl-2 inhibitors and have experience in incorporating novel biomarkers into trial design.
 - a. Yan F, Li J, Milosevic J, Petroni R, Liu S, Shi Z, Yuan S, Reynaga JM, Qi Y, Rico J, Yu S, Liu Y, Rokudai S, **Palmisiano N**, Meyer SE, Sung PJ, Wan L, Lan F, Garcia BA, Stanger BZ, Sykes DB, Blanco MA. KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs. *Cancer Discov.* 2022 Mar 1;12(3):792-811. doi: 10.1158/2159-8290.CD-20-1459. PMID: 34853079; PMCID: PMC8916037.
 - b. Jeurkar C, Wilde L, Leiby BE, Banks J, Kasner M, Keiffer G, Filicko-O'Hara J, **Palmisiano N**. Inpatient versus outpatient hypomethylating agent induction for acute myeloid leukemia as a predictor for survival. *Leuk Res.* 2021 Apr;103:106533. doi: 10.1016/j.leukres.2021.106533. Epub 2021 Feb 13. PMID: 33621825.
 - c. McBride A, Houtmann S, Wilde L, Vigil C, Eischen CM, Kasner M, **Palmisiano N**. The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome. *Front Oncol.* 2019 Mar 27;9:192. doi: 10.3389/fonc.2019.00192. PMID: 30972300; PMCID: PMC6445951.
2. **Improving outcomes after hematopoietic stem cell transplant:** I have also focused on research that in how to improve outcomes after hematopoietic stem cell transplantation. Specifically, my research has focused on the interaction between comorbid conditions, such as obesity, smoking status, age, and survival. In addition, I am also interested in how different conditioning regimens and cell processing affects outcome after transplant.
 - a. Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, **Palmisiano N**, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. *Blood Adv.* 2020 Jul 14;4(13):3180-3190. doi: 10.1182/bloodadvances.2019001266. Erratum in: *Blood Adv.* 2021 Jul 13;5(13):2752. PMID: 32663298; PMCID: PMC7362362.
 - b. Grosso D, Carabasi M, Filicko-O'Hara J, Wagner JL, O'Hara W, Sun M, Colombe B, Shi W, Werner-Wasik M, Rudolph S, Alpdogan O, Binder A, Kasner M, Klumpp T, Martinez-Outschoorn U, **Palmisiano N**, Wilde L, Porcu P, Gergis U, Flomenberg N. Low Nonrelapse Mortality after HLA-Matched Related 2-Step Hematopoietic Stem Cell Transplantation Using Cyclophosphamide for Graft-versus-Host Disease Prophylaxis and the Potential Impact of Non- Cyclophosphamide-Exposed T Cells on Outcomes. *Biol Blood Marrow Transplant.* 2020 Oct;26(10):1861-1867. doi: 10.1016/j.bbmt.2020.06.021. Epub 2020 Jul 3. PMID: 32629157.
 - c. Laothamatas, K.C., Bekker, T.D., Leiby, B.E., Gandhi, K., Kasner, M.K., Vaid, U. & **Palmisiano, N.D.** Mortality outcomes in hospitalized oncology patients after rapid response team activation, *Journal of Community and Supportive Oncology*, 2018, 16, E250-E255.

- d. Gaballa S, **Palmisiano N**, Alpdogan O, Carabasi M, Filicko-O'Hara J, Kasner M, Kraft WK, Leiby B, Martinez-Outschoorn U, O'Hara W, Pro B, Rudolph S, Sharma M, Wagner JL, Weiss M, Flomenberg N, Grosso D. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2016 Jan;22(1):141-8. doi: 10.1016/j.bbmt.2015.09.017. Epub 2015 Sep 28. PMID: 26415558.

Complete List of Published Work: <https://www.ncbi.nlm.nih.gov/pubmed/?term=Palmisiano+N>